SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
Phase 2
Completed
- Conditions
- InfluenzaOrthomyxovirus InfectionsMyxovirus Infection
- Interventions
- Biological: Inactivated, split-virion, influenza vaccineBiological: Inactivated, split-virion influenza vaccine
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 160
- Registration Number
- NCT00776438
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
Phase 2
Completed
- Conditions
- Myxovirus InfectionInfluenzaOrthomyxovirus Infection
- Interventions
- Biological: Influenza Virus Vaccine USP Trivalent Types A and B
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 807
- Registration Number
- NCT00775450
Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults
Phase 2
Terminated
- Conditions
- MeningitisMeningococcemia
- Interventions
- Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 18
- Registration Number
- NCT00772629
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
Completed
- Conditions
- Haemophilus InfectionTetanusPertussisDiphtheriaPolio
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3214
- Registration Number
- NCT00772369
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
Phase 2
Completed
- Conditions
- MeningococcemiaNeisseria MeningitidisMeningitis
- Interventions
- Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 173
- Registration Number
- NCT00772070
Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection
Phase 2
Completed
- Conditions
- DiarrheaClostridium Difficile Infection
- Interventions
- Biological: 0.9% Normal SalineBiological: Clostridium difficile toxoid vaccineBiological: Clostridium difficile toxoid vaccine with adjuvant
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 116
- Registration Number
- NCT00772343
- Locations
- 🇬🇧
Royal Oldham Hospital, Manchester, United Kingdom
🇬🇧St. Richard's Hospital, Chichester, United Kingdom
🇬🇧Blackpool Victoria Hospital, Blackpool, United Kingdom
Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
Phase 2
Completed
- Conditions
- MeningococcemiaMeningitis
- Interventions
- Biological: Haemophilus Influenzae Type b (Hib) vaccineBiological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 103
- Registration Number
- NCT00771849
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
Phase 3
Completed
- Conditions
- Orthomyxoviridae InfectionMyxovirus InfectionInfluenza
- Interventions
- Biological: Influenza Virus Vaccine USP Trivalent Types A and B
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 4292
- Registration Number
- NCT00772109
Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®
Phase 4
Completed
- Conditions
- Orthomyxoviridae InfectionsInfluenza
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 32
- Registration Number
- NCT00755274
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
Phase 2
Completed
- Conditions
- West Nile Fever
- Interventions
- Biological: PlaceboBiological: ChimeriVax-WN02 vaccine
- First Posted Date
- 2008-09-04
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 479
- Registration Number
- NCT00746798
- Locations
- 🇺🇸
Big Sky Clinical Research, Butte, Montana, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Bio-Kinetic, Springfield, Missouri, United States
© Copyright 2025. All Rights Reserved by MedPath